Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 188

1.

The effect of initiating combined antiretroviral therapy on endothelial cell activation and coagulation markers in South African HIV-infected individuals.

Jong E, Louw S, van Gorp EC, Meijers JC, ten Cate H, Jacobson BF.

Thromb Haemost. 2010 Dec;104(6):1228-34. doi: 10.1160/TH10-04-0233. Epub 2010 Sep 30.

PMID:
20886182
2.

The hemostatic balance in HIV-infected patients with and without antiretroviral therapy: partial restoration with antiretroviral therapy.

Jong E, Louw S, Meijers JC, de Kruif MD, ten Cate H, Büller HR, Mulder JW, van Gorp EC.

AIDS Patient Care STDS. 2009 Dec;23(12):1001-7. doi: 10.1089/apc.2009.0173.

PMID:
19929230
3.

The effect of tuberculosis treatment on virologic and immunologic response to combination antiretroviral therapy among South African children.

Soeters HM, Sawry S, Moultrie H, Rie AV.

J Acquir Immune Defic Syndr. 2014 Oct 1;67(2):136-44. doi: 10.1097/QAI.0000000000000284.

4.

D-Dimer Levels and Vitamin K Antagonist Therapy in Deep Vein Thrombosis of the Legs.

Park JK, Koo do H, Yoon DH, Lee JN.

Ann Vasc Surg. 2016 Jul;34:119-34. doi: 10.1016/j.avsg.2015.11.038. Epub 2016 May 10.

PMID:
27177705
5.

The evaluation of platelet indices and markers of inflammation, coagulation and disease progression in treatment-naïve, asymptomatic HIV-infected individuals.

Nkambule BB, Davison GM, Ipp H.

Int J Lab Hematol. 2015 Aug;37(4):450-8. doi: 10.1111/ijlh.12307. Epub 2014 Nov 17.

PMID:
25401263
6.

Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study.

Mocroft A, Phillips AN, Gatell J, Ledergerber B, Fisher M, Clumeck N, Losso M, Lazzarin A, Fatkenheuer G, Lundgren JD; EuroSIDA study group.

Lancet. 2007 Aug 4;370(9585):407-13.

PMID:
17659333
7.

Feasibility and effectiveness of early initiation of combination antiretroviral therapy in HIV-infected infants in a government clinic of Kwazulu-Natal, South Africa.

Purchase SE, Van der Linden DJ, McKerrow NH.

J Trop Pediatr. 2012 Apr;58(2):114-9. doi: 10.1093/tropej/fmr053. Epub 2011 Jun 24.

PMID:
21705764
8.

Endothelial dysfunction, increased inflammation, and activated coagulation in HIV-infected patients improve after initiation of highly active antiretroviral therapy.

Arildsen H, Sørensen KE, Ingerslev JM, Østergaard LJ, Laursen AL.

HIV Med. 2013 Jan;14(1):1-9. doi: 10.1111/j.1468-1293.2012.01027.x. Epub 2012 May 28.

9.

Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the prolong study.

Cosmi B, Legnani C, Iorio A, Pengo V, Ghirarduzzi A, Testa S, Poli D, Tripodi A, Palareti G; PROLONG Investigators (on behalf of FCSA, Italian Federation of Anticoagulation Clinics).

Eur J Vasc Endovasc Surg. 2010 Mar;39(3):356-65. doi: 10.1016/j.ejvs.2009.11.022. Epub 2010 Jan 19.

10.

Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection.

Baker JV, Neuhaus J, Duprez D, Kuller LH, Tracy R, Belloso WH, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Nixon DE, Paton NI, Neaton JD; INSIGHT SMART Study Group.

J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):36-43. doi: 10.1097/QAI.0b013e3181f7f61a.

11.

Long-term efficacy and safety of once-daily enoxaparin plus warfarin for the outpatient ambulatory treatment of lower-limb deep vein thrombosis in the TROMBOTEK trial.

Kurtoglu M, Koksoy C, Hasan E, Akcalı Y, Karabay O, Filizcan U; TROMBOTEK Study Group.

J Vasc Surg. 2010 Nov;52(5):1262-70. doi: 10.1016/j.jvs.2010.06.070. Epub 2010 Aug 21.

12.

Disparities in Initiation of Combination Antiretroviral Treatment and in Virologic Suppression Among Patients in the HIV Outpatient Study, 2000-2013.

Novak RM, Hart RL, Chmiel JS, Brooks JT, Buchacz K; HIV Outpatient Study (HOPS) Investigators.

J Acquir Immune Defic Syndr. 2015 Sep 1;70(1):23-32. doi: 10.1097/QAI.0000000000000652.

PMID:
25886926
13.

Effect of gender and calendar year on time to and duration of virologic suppression among antiretroviral-naïve HIV-infected individuals initiating combination antiretroviral therapy.

Raboud J, Blitz S, Walmsley S, Thompson C, Rourke SB, Loutfy MR; Ontario HIV Treatment Network Cohort Study Team.

HIV Clin Trials. 2010 Nov-Dec;11(6):340-50. doi: 10.1310/hct1106-340.

PMID:
21239362
14.

Outcomes of second-line combination antiretroviral therapy for HIV-infected patients: a cohort study from Rio de Janeiro, Brazil.

Cardoso SW, Luz PM, Velasque L, Torres TS, Tavares IC, Ribeiro SR, Moreira RI, Veloso VG, Moore RD, Grinsztejn B.

BMC Infect Dis. 2014 Dec 19;14:699. doi: 10.1186/s12879-014-0699-5.

15.

Association of clinical and therapeutic factors with incident dyslipidemia in a cohort of human immunodeficiency virus-infected and non-infected adults: 1994-2011.

Tripathi A, Jerrell JM, Liese AD, Zhang J, Rizvi AA, Albrecht H, Duffus WA.

Metab Syndr Relat Disord. 2013 Dec;11(6):417-26. doi: 10.1089/met.2013.0017. Epub 2013 Aug 2.

PMID:
23909647
16.

Evidence for innate immune system activation in HIV type 1-infected elite controllers.

Krishnan S, Wilson EM, Sheikh V, Rupert A, Mendoza D, Yang J, Lempicki R, Migueles SA, Sereti I.

J Infect Dis. 2014 Mar;209(6):931-9. doi: 10.1093/infdis/jit581. Epub 2013 Nov 1.

17.

Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.

Holkmann Olsen C, Mocroft A, Kirk O, Vella S, Blaxhult A, Clumeck N, Fisher M, Katlama C, Phillips AN, Lundgren JD; EuroSIDA study group.

HIV Med. 2007 Mar;8(2):96-104.

18.

Safety and effectiveness of combination antiretroviral therapy during the first year of treatment in HIV-1 infected Rwandan children: a prospective study.

Mutwa PR, Boer KR, Asiimwe-Kateera B, Tuyishimire D, Muganga N, Lange JM, van de Wijgert J, Asiimwe A, Reiss P, Geelen SP.

PLoS One. 2014 Nov 3;9(11):e111948. doi: 10.1371/journal.pone.0111948. eCollection 2014.

19.

Long-term suppressive combined antiretroviral treatment does not normalize the serum level of soluble CD14.

Méndez-Lagares G, Romero-Sánchez MC, Ruiz-Mateos E, Genebat M, Ferrando-Martínez S, Muñoz-Fernández MÁ, Pacheco YM, Leal M.

J Infect Dis. 2013 Apr 15;207(8):1221-5. doi: 10.1093/infdis/jit025. Epub 2013 Jan 15.

PMID:
23322858
20.

Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption.

Wyl Vv, Gianella S, Fischer M, Niederoest B, Kuster H, Battegay M, Bernasconi E, Cavassini M, Rauch A, Hirschel B, Vernazza P, Weber R, Joos B, Günthard HF; Swiss HIV Cohort Study-SHCS.

PLoS One. 2011;6(11):e27463. doi: 10.1371/journal.pone.0027463. Epub 2011 Nov 15.

Supplemental Content

Support Center